Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

From cold chain to ambient: Benefits, risks, and evidence across cell therapy logistics

  • Gostage, John
  • Domingo-López, Daniel A.
  • Tarpey, Ruth
  • Duffy, Garry P.
  • Levey, Ruth E.
With the exponential growth in the number of cell-based therapies, there is a need to look more closely at a critical factor that unites all these therapies, i.e., cryopreservation, which is currently deemed the gold standard for the storage and shipment of cells. Although cryopreservation is an integral tool in research and clinical practice, it can cause logistical issues (associated with cold chain transport), financial strain, cell dysfunction, and reduced cell viability. Many cell types that are currently being used in cell therapy, or have high clinical potential, have shown to be affected by cryopreservation. Research groups regularly highlight the need for optimized cryopreservation techniques as well as novel alternatives to avoid cryoprotectants. Here, we highlight the potential of ambient cell transport and how, by optimizing three key elements, nutrient, oxygen, and structural support, it may be possible to avoid cryopreservation during cell transport. Ambient cell transport has various benefits including circumventing ultra-low temperatures during shipment, avoidance of cryopreservation-induced cell damage, and offering a more cost-effective and accessible cell transport option. As the cell therapy field evolves, we must actively evolve with it and explore new ways to ensure effective transport of potent, viable, and efficacious cell-based treatments., This publication has emanated from research conducted with the financial support of Taighde Éireann – Research Ireland’s National Challenge Fund under grant number 22/NCF/DR/11293 and Taighde Éireann – Research Ireland under grant number 13/ RC/2073_P2 at . D.A.D.-L. was funded by the European Union’s Horizon Europe research and innovation program un- der the Marie Skłodowska-Curie grant agreement No 101153515., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Extracellular matrix remodeling therapeutic strategies to tackle central nervous system diseases

  • Domingo-López, Daniel A.
  • Aguilar de Armas, María Rosa
  • Martín-Saldaña, Sergio
Neurodegenerative diseases are a global burden due to the increased life expectancy. Neuroinflammation is not only a result of neurodegeneration but a key player in the initiation and onset of it. Due to the inherent complexity of these diseases, there is a need for the development of better treatments, as well as the discovery of new therapeutic targets. In this sense, knowledge about extracellular matrix remodeling after injury in the central nervous system was overseen for a century, but it has blossomed in the last three decades. Nowadays, we possess strong evidence regarding the imbalance, over-synthesis, and changes in the organization of most key components of the extracellular matrix after neuroinflammation and neurodegeneration. Thus, hyaluronic acid, chondroitin sulphate proteoglycans, or fibronectin presented an impairment in their anabolism and catabolism, which could be a cause or a consequence of the inflammatory and degenerative process. Regardless, it is clear that extracellular matrix remodeling plays a pivotal role in the onset and resolution of inflammation-driven neurological disorders by creating a non-permissive niche for self-restoration of the neural homeostasis. Despite being an emerging area of study, extracellular matrix changes have been explored in the last decades in the central nervous system to shed light on their potential as diagnostic markers as well as therapeutic targets. The extracellular matrix fingerprint in diseases such as multiple sclerosis, Alzheimer's disease, Parkinson's disease, or stroke has been described both in preclinical models and in post-mortem clinical samples. Herein, we provided an overview of the state of the art of extracellular matrix components and function in the central nervous system, both under homeostasis and in neurodegeneration. Then, we critically revise the therapeutic efforts targeting the extracellular matrix, aiming to tackle neurodegenerative disorders. Altogether, this review contextualizes the current understanding of extracellular matrix in the central nervous system and its remodeling after neuroinflammation, its role in disease onset and resolution, and how this knowledge is being applied to the development of new therapeutic approaches., This work has received funding from Centro de Investigación Biomédica en Red, Instituto de Salud Carlos III Ref. CB06/01/0013; Grant PID2023-149301OB-I00 funded by MICIU/AEI/10.13039/501100011033 and by ERDF/EU Grant S2022/BMD-7406 funded by Comunity of Madrid (Spain) (all to SMS); the European Union’s Horizon Europe research and innovation programme under the Marie Skłodowska-Curie grant agreement No. 101153515 (to DADL)., Peer reviewed